Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Methanococcus maripaludis 50S ribosomal protein L3P (rpl3p) CSB-YP409492MNR
CSB-EP409492MNR
CSB-BP409492MNR
CSB-MP409492MNR
CSB-EP409492MNR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus maripaludis Tetrahydromethanopterin S-methyltransferase subunit C (mtrC), partial CSB-YP409493MNR
CSB-EP409493MNR
CSB-BP409493MNR
CSB-MP409493MNR
CSB-EP409493MNR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus maripaludis 30S ribosomal protein S15P/S13e (rps15p) CSB-YP409494MNR
CSB-EP409494MNR
CSB-BP409494MNR
CSB-MP409494MNR
CSB-EP409494MNR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus maripaludis Aspartate--tRNA ligase (aspS) CSB-YP409495MNR
CSB-EP409495MNR
CSB-BP409495MNR
CSB-MP409495MNR
CSB-EP409495MNR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus maripaludis Ribosome biogenesis protein Nop10 (MmarC7_0981) CSB-YP409496MNR
CSB-EP409496MNR
CSB-BP409496MNR
CSB-MP409496MNR
CSB-EP409496MNR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus maripaludis GTP cyclohydrolase mptA (mptA) CSB-YP409497MNR
CSB-EP409497MNR
CSB-BP409497MNR
CSB-MP409497MNR
CSB-EP409497MNR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus maripaludis 50S ribosomal protein L31e (rpl31e) CSB-YP409498MNR
CSB-EP409498MNR
CSB-BP409498MNR
CSB-MP409498MNR
CSB-EP409498MNR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus maripaludis Pyridoxal biosynthesis lyase pdxS (pdxS) CSB-YP409499MNR
CSB-EP409499MNR
CSB-BP409499MNR
CSB-MP409499MNR
CSB-EP409499MNR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus maripaludis DNA-binding protein MmarC7_1157 (MmarC7_1157) CSB-YP409500MNR
CSB-EP409500MNR
CSB-BP409500MNR
CSB-MP409500MNR
CSB-EP409500MNR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus maripaludis 7-cyano-7-deazaguanine synthase (queC) CSB-YP409501MNR
CSB-EP409501MNR
CSB-BP409501MNR
CSB-MP409501MNR
CSB-EP409501MNR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus maripaludis 50S ribosomal protein L1P (rpl1p) CSB-YP409502MNR
CSB-EP409502MNR
CSB-BP409502MNR
CSB-MP409502MNR
CSB-EP409502MNR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus maripaludis Translation initiation factor 2 subunit beta (eIF2B) CSB-YP409503MNR
CSB-EP409503MNR
CSB-BP409503MNR
CSB-MP409503MNR
CSB-EP409503MNR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus maripaludis Phosphoribosylamine--glycine ligase (purD) CSB-YP409504MNR
CSB-EP409504MNR
CSB-BP409504MNR
CSB-MP409504MNR
CSB-EP409504MNR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus maripaludis Ribonuclease P protein component 3 (rnp3) CSB-YP409505MNR
CSB-EP409505MNR
CSB-BP409505MNR
CSB-MP409505MNR
CSB-EP409505MNR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus maripaludis Fibrillarin-like rRNA/tRNA 2'-O-methyltransferase (flpA) CSB-YP409506MNR
CSB-EP409506MNR
CSB-BP409506MNR
CSB-MP409506MNR
CSB-EP409506MNR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus maripaludis 50S ribosomal protein L14e (rpl14e) CSB-YP409507MNR
CSB-EP409507MNR
CSB-BP409507MNR
CSB-MP409507MNR
CSB-EP409507MNR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus maripaludis 30S ribosomal protein S28e (rps28e) CSB-YP409508MNR
CSB-EP409508MNR
CSB-BP409508MNR
CSB-MP409508MNR
CSB-EP409508MNR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus maripaludis 30S ribosomal protein S3Ae (rps3Ae) CSB-YP409509MNR
CSB-EP409509MNR
CSB-BP409509MNR
CSB-MP409509MNR
CSB-EP409509MNR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Actinobacillus succinogenes Formamidopyrimidine-DNA glycosylase (mutM) CSB-YP409510AUG
CSB-EP409510AUG
CSB-BP409510AUG
CSB-MP409510AUG
CSB-EP409510AUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Actinobacillus succinogenes DNA-directed RNA polymerase subunit beta' (rpoC), partial CSB-YP409511AUG
CSB-EP409511AUG
CSB-BP409511AUG
CSB-MP409511AUG
CSB-EP409511AUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>